Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service peripheral arterial intervention cases in North Carolina: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 8% on average (237 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 70 | 7,398 | 40% |
| 2020 | 67 | 7,080 | 43% |
| 2021 | 64 | 7,176 | 48% |
| 2022 | 50 | 6,026 | 52% |
| 2023 | 38 | 5,191 | 56% |
| 2024 | 34 | 4,853 | 59% |
| 2025 from claims | – | 4,554 4,179–4,818 | 61% |
| 2026 forecast | – | 4,586 4,035–5,292 | 62% |
| 2027 forecast | – | 4,599 3,932–5,481 | 62% |
| 2028 forecast | – | 4,610 3,847–5,645 | 63% |
| 2029 forecast | – | 4,618 3,772–5,791 | 64% |
| 2030 forecast | – | 4,623 3,704–5,924 | 65% |
Iliac, femoropopliteal, and tibial angioplasty, stenting, atherectomy. Professional codes (what the surgeon bills): CPT 37220, 37221, 37224, 37225, 37226, 37227, 37228, 37229, 37230, 37231; the hospital bills MS-DRG 252, 253, 254.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 63% of the cases CMS names in North Carolina; 17 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 20% inpatient hospital, 41% hospital outpatient, 39% office. The share outside the hospital has moved +5 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 132 | 20,074−3.1%/yr | −3.1%/yr | 8.5 | 70% | 23,800 in 2030+2.9%/yr |
| Texas | 128 | 16,813−7.6%/yr | −7.6%/yr | 7.4 | 58% | 19,600 in 2030+2.6%/yr |
| Maryland | 52 | 6,992−4.8%/yr | −4.8%/yr | 7.7 | 84% | 8,070 in 2030+2.4%/yr |
| Tennessee | 45 | 5,546−6.3%/yr | −6.3%/yr | 7.5 | 70% | 6,500 in 2030+2.7%/yr |
| Virginia | 30 | 3,751−7.6%/yr | −7.6%/yr | 3.5 | 43% | 5,530 in 2030+6.7%/yr |
| Georgia | 21 | 3,651−12%/yr | −12%/yr | 4.0 | 46% | 4,960 in 2030+5.3%/yr |
| Arkansas | 23 | 2,979−1.4%/yr | −1.4%/yr | 7.6 | 45% | 2,520 in 2030−2.8%/yr |
| Louisiana | 12 | 2,691−14%/yr | −14%/yr | 6.3 | 32% | 2,760 in 2030+0.4%/yr |
| South Carolina | 19 | 2,514−4.5%/yr | −4.5%/yr | 3.5 | 25% | 3,310 in 2030+4.7%/yr |
| Oklahoma | 19 | 2,386−5.2%/yr | −5.2%/yr | 4.7 | 47% | 3,400 in 2030+6.1%/yr |
| Mississippi | 27 | 2,361−7.9%/yr | −7.9%/yr | 6.1 | 73% | 2,320 in 2030−0.3%/yr |
| Alabama | 19 | 2,322−11%/yr | −11%/yr | 5.0 | 47% | 2,130 in 2030−1.4%/yr |
| Kentucky | 22 | 2,281−6.3%/yr | −6.3%/yr | 4.7 | 43% | 2,570 in 2030+2%/yr |
| District of Columbia | 10 | 1,226+9.5%/yr | +9.5%/yr | 18.9 | 83% | 1,830 in 2030+6.9%/yr |
| Delaware | 8 | 910−1%/yr | −1%/yr | 5.2 | 79% | 2,020 in 2030+14%/yr |
| West Virginia | 5 | 769−11%/yr | −11%/yr | 3.5 | 0% | 840 in 2030+1.4%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Dialysis access | 55 | 5,158−18%/yr | −18%/yr | 5.41.0× | 66% | 4,610 in 2030−1.9%/yr |
| Superficial venous ablation | 57 | 4,216−3.9%/yr | −3.9%/yr | 4.00.6× | 97% | 3,890 in 2030−1.3%/yr |
| Thrombectomy, IVC filters & venous stents | 4 | 1,069−0.8%/yr | −0.8%/yr | 1.10.6× | 0% | 1,460 in 2030+5.4%/yr |
| Carotid revascularization | 17 | 916−10%/yr | −10%/yr | 0.90.7× | 0% | 940 in 2030+0.4%/yr |
| Aortic endografts (EVAR/TEVAR) | 3 | 449−8.3%/yr | −8.3%/yr | 0.50.9× | 0% | 420 in 2030−1.1%/yr |
Peripheral arterial intervention in every state, and its device makers · Every procedure market in North Carolina · Every state · Compare with Florida
Medtronic leads with 45% of company spending on these surgeons in 2025, +4 pts on 2024.
In 2025, 10 companies reported engagement with North Carolina’s surgeons worth $79K in consulting, speaking, meals and travel tied to these products, about $2,337 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 58 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
For MS-DRG 254 (other vascular procedures without cc/mcc), commercial plans pay North Carolina’s hospitals a median of $28K, from $24K at the lowest to $28K at the highest, across 8 hospitals that publish a price.
Each hospital’s median over its commercial plans, from the machine-readable files hospitals must post; not every hospital is loaded.